Mary J. Savage - Concepedia

Author

Mary J. Savage

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

M Savage, M. J. Savage, M. Savage, M.J. Savage, Marc Walton, Mary J Savage, Mary J. Savage, Mary Josephine Savage, Mary Savage, Savage, Mary

111

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy Memorial Sloan Kettering Cancer Center NYU Langone Health Erasmus MC Cancer Institute

About

Mary J. Savage is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, neuroscience, and alzheimer's disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	28	3.3K
2	Social Sciences	6	6	727
3	Health Sciences	4	4	159
4	Natural Sciences	4	4	185
5	Engineering	1	1	58

Mary J. Savage

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, The Lancet Oncology First-line PembrolizumabUrologyMetastatic Urothelial CancerGenitourinary CancerMedicine	2017	1.3K
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer Karina Kulangara, Nancy R. Zhang, Ellie Corigliano, Archives of Pathology & Laboratory Medicine	2018	514
Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model Is Associated with Amyloid Deposition Mary J. Savage, Yin‐Guo Lin, John R. Ciallella, Journal of Neuroscience Cell DeathNeurochemical BiomarkersSocial SciencesNeuroinflammationAlzheimer's Disease	2002	289
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Journal of Clinical Oncology	2020	283
Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol David Howland, Stephen P. Trusko, Mary J. Savage, Journal of Biological Chemistry	1998	256
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study Yung‐Jue Bang, Yoon‐Koo Kang, Daniel V.T. Catenacci, Gastric Cancer	2019	242
AMPA receptor downscaling at the onset of Alzheimer’s disease pathology in double knockin mice Eric H. Chang, Mary J. Savage, Dorothy G. Flood, Proceedings of the National Academy of Sciences Double Knockin MiceNeurotransmissionAmyloid Precursor ProteinSynaptic SignalingSocial Sciences	2006	223
Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester Mary J. Savage, Stephen P. Trusko, David Howland, Journal of Neuroscience Amyloid Precursor ProteinAlzheimer's DiseaseDegenerative PathologyProtein MisfoldingNeurology	1998	210
CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family Anna C. Maroney, James P. Finn, Thomas J. Connors, Journal of Biological Chemistry	2001	204
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial Alasdair Munro, Shuo Feng, Leila Janani, The Lancet Infectious Diseases	2022	170

Page 1